Terbutaline chemical structure
Find information on thousands of medical conditions and prescription drugs.

Terbutaline

The drug Terbutaline (trade names Brethine, Bricanyl, or Brethaire) is a β2-adrenergic receptor agonist, used as a fast-acting bronchodilator and as a tocolytic to delay premature labour.

Terbutaline as a treatment for premature labour is an off-label use not approved by the FDA. Recent studies have suggested that terbutaline is a developmental neurotoxicant and may cause brain damage to the infant. (J Pharmacol Exp Ther. 2004 Feb;308(2):529-37. Epub 2003 Nov 10.)

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Value of oral terbutaline after successful tocolysis - includes editor note - adapted from the American Journal of Obstetrics and Gynecology 1995;173:1518-22
From American Family Physician, 4/1/96 by Barbara Apgar

Preterm births account for 75 to 80 percent of perinatal deaths. Up to 30 percent of infants who survive may have persistent mental, neurologic or respiratory dysfunction. Parenteral tocolytic therapy has been used with reasonable success to stop premature uterine contractions. How and associates performed a prospective, randomized trial to determine whether patients benefit from use of maintenance oral terbutaline after successful intravenous tocolysis to prevent subsequent premature uterine contractions.

The study included a total of 184 patients with preterm uterine contractions. After contractions were successfully stopped with magnesium sulfate therapy, the patients were discharged from the hospital to receive continuous bed rest either with or without oral terbutaline (5 to 10 mg every four to six hours). Patients were assigned to one of four groups: (1) those with a Bishop score of 5 or more who were given oral terbutaline, (2) those with a Bishop score of 5 or more who were not given oral terbutaline, (3) those with a Bishop score of less than 5 who were given oral terbutaline, and (4) those with a Bishop score of less than 5 who were not given oral terbutaline. Oral terbutaline was discontinued at 37 weeks of gestation. Home uterine monitoring devices were not used in the study

No statistically significant differences were observed in maternal age, parity, race, duration of intravenous tocolysis or duration of hospital stay among the four groups. No significant differences occurred in the mode of delivery, readmissions, or the number of unscheduled hospital visits among the groups. Of the patients in group 1,16.0 percent subsequently presented with preterm premature rupture of the membranes (PROM); in group 2,5.7 percent had preterm PROM; 2.4 percent in group 3 had preterm PROM, and 5.0 percent in group 4 had preterm PROM. Compared with patients with a Bishop score less than 5, patients with a Bishop score of 5 or more had a significantly lower gestational age at delivery and lower percentage of deliveries at 37 weeks or later. However, no significant differences in these characteristics were found when group 1 was compared with group 2 and when group 3 was compared with group 4. Culture results did not differ significantly among the groups.

The neonatal outcome demonstrated no differences with respect to neonatal morbidity. A comparison of patients randomized to the oral terbutaline arm and the arm not receiving oral terbutaline revealed no differences in relevant maternal clinical characteristics or in pregnancy and neonatal outcome.

The authors conclude that oral terbutaline maintenance therapy does no improve pregnancy outcome in patient who have had successful intravenous tocolysis for premature onset of labor. (How HY, et al. Oral terbutaline in the outpatient management of preterm labor. Am J Obstet Gynecol 1995;173:1518-22.)

EDITOR'S NOTE: Premature births exact an enormous toll on families and society at large. Numerous nonrandomized trials have pointed to the efficacy of tocolysis in stopping premature uterine contractions. However, its efficacy in effectively changing pregnancy outcome has not been proven. Findings of this randomized study demonstrate that oral terbutaline does not prolong pregnancy and is no better than bed rest alone. The efficacy of other tocolytics, such as nifedipine and indocin, should be evaluated in the future.

COPYRIGHT 1996 American Academy of Family Physicians
COPYRIGHT 2004 Gale Group

Return to Terbutaline
Home Contact Resources Exchange Links ebay